Francois Brisebois
Stock Analyst at Oppenheimer
(1.75)
# 3,398
Out of 5,135 analysts
73
Total ratings
39.51%
Success rate
-1.42%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $3.83 | +108.88% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.59 | +7.33% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $26.25 | +204.76% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.12 | +212.50% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.46 | +173.97% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $63.27 | +13.80% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $35.28 | +72.90% | 6 | Jan 13, 2025 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $11.04 | +153.62% | 2 | Nov 6, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $328.93 | -50.45% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $15.38 | +257.61% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.38 | +3,847.37% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.61 | -30.27% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.19 | +162.53% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $25.04 | -44.09% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $12.18 | +433.66% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.02 | +99.20% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.13 | +110.16% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.31 | +64,835.06% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.14 | +473,584.21% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.59 | +324.71% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.68 | +389.13% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $8.45 | +491.72% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.59 | +551,671.12% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $3.83
Upside: +108.88%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.59
Upside: +7.33%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $26.25
Upside: +204.76%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.12
Upside: +212.50%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.46
Upside: +173.97%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $63.27
Upside: +13.80%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $35.28
Upside: +72.90%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.04
Upside: +153.62%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $328.93
Upside: -50.45%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $15.38
Upside: +257.61%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.38
Upside: +3,847.37%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.61
Upside: -30.27%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.19
Upside: +162.53%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $25.04
Upside: -44.09%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $12.18
Upside: +433.66%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.02
Upside: +99.20%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.13
Upside: +110.16%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.31
Upside: +64,835.06%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.14
Upside: +473,584.21%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.59
Upside: +324.71%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.68
Upside: +389.13%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $8.45
Upside: +491.72%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.59
Upside: +551,671.12%